Hyperthyroidism in thyroid carcinoma originating in struma ovarii

被引:0
作者
Mesquita, Juliana Bezerra [1 ]
Biscolla, Rosa Paula M. [2 ,3 ]
机构
[1] Liga Norte Riograndense o Canc, Natal, Brazil
[2] Univ Fed Sao Paulo, Thyroid Dis Ctr, Escola Paulista Med, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Med, Div Endocrinol, Lab Mol & Translat Endocrinol,Escola Paulista Med, Sao Paulo, Brazil
关键词
thyroid carcinoma; Struma ovarii; hyperthyroidism; thyroid ectopic cancer;
D O I
10.1530/EDM-24-0082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid carcinoma originating in Struma Ovarii (SO) is a rare thyroid ectopic cancer that accounts for 0.01% of all ovarian malignancies and is associated with hyperthyroidism in less than 15% of cases. In a 44-year-old patient with pelvic pain, the CT scan revealed a solid-cystic formation in the ovarium. A left oophorectomy was performed and showed a borderline serous tumor and papillary thyroid carcinoma ('thyroid carcinoma originating in Struma Ovarii') measuring 10 cm. Thyroid function was assessed, and hyperthyroidism was diagnosed. Surgical complementation and a pelvic re-approach were performed. The histological findings showed a papillary thyroid carcinoma in the uterine serosa and the right adnexa. Thyroid function was re-evaluated, and despite normal thyroid function, the TRAb test remained positive. The patient underwent total thyroidectomy and radioiodine therapy (RIT), after which the TRAb test became negative. During 3 years of follow-up, no evidence of tumor was observed. In our case of thyroid carcinoma originating in SO, hyperthyroidism was treated with ovarian surgery, total thyroidectomy, and RIT. It is worth noting that thyroid function was normalized after ovarian surgery, but the TRAb test only became negative after total thyroidectomy. We hope to draw attention to the importance of evaluating thyroid function in patients with SO and treating high-risk SO patients with RIT after total thyroidectomy to achieve disease remission.
引用
收藏
页数:4
相关论文
共 12 条
  • [1] Tan A, Stewart CJ, Garrett KL, Rye M, Cohen PA., Novel BRAF and KRAS mutations in papillary thyroid carcinoma arising in struma ovarii, Endocrine Pathology, 26, pp. 296-301, (2015)
  • [2] Grandet PJ, Remi MH., Struma ovarii with hyperthyroidism, Clinical Nuclear Medicine, 25, pp. 763-765, (2000)
  • [3] Yoo SC, Chang KH, Lyu MO, Chang SJ, Ryu HS, Kim HS., Clinical characteristics of struma ovarii, Journal of Gynecologic Oncology, 19, pp. 135-138, (2008)
  • [4] Plaut A., Ovarian struma: a morphologic, pharmacologic, and biologic examination, American Journal of Obstetrics and Gynecology, 25, pp. 351-359, (1933)
  • [5] Mimura Y, Kishida M, Masuyama H, Suwaki N, Kodama J, Otsuka F, Kataoka H, Yamauchi T, Ogura T, Kudo T, Et al., Coexistence of Graves’ disease and struma ovarii: case report and literature review, Endocrine Journal, 48, pp. 255-260, (2001)
  • [6] Zhang R, Tian X, Luo Y, Dong H, Tian W, Zhang Y, Li D, Sun H, Meng Z., Case report: recurrent malignant struma ovarii with hyperthyroidism and metastases, a rare case report and review of the literature, Pathology Oncology Research, 28, (2022)
  • [7] Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, Bean S, Krigman HR, Roth LM, Young RH., Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread, International Journal of Gynecological Pathology, 28, pp. 405-422, (2009)
  • [8] Marcus CC, Marcus SL., Struma ovarii. A report of 7 cases and a review of the subject, American Journal of Obstetrics and Gynecology, 81, pp. 752-762, (1961)
  • [9] Yoshioka W, Miyauchi A, Ito M, Kudo T, Tamai H, Nishihara E, Kihara M, Miya A, Amino N., Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves’ disease, Endocrine Journal, 63, pp. 179-185, (2016)
  • [10] Yassa L, Sadow P, Marqusee E., Malignant struma ovarii. Nature Clinical Practice, Endocrinology and Metabolism, 4, pp. 469-472, (2008)